Foresite Capital is an equity firm focused on healthcare growth. It has just announced that Molly He, Ph.D., will be joining in as a venture partner. Dr. Jim Tananbaum was earlier a senior director at Illumina. She has over 15 years of experience in research and development of pharmaceuticals and genomes.
In an article on INC42, Jim Tananbaum is the CEO as well as Managing Director of Foresite Capital. He stated that Dr. He is a highly respected scientific researcher in this field of next-generation sequencing. Hence she would be a welcome addition to the team. Jim Tananbaum further stated that she has extensive experience in genomics as well as drug development. She has a remarkable track record of innovative leadership too. Hence she can make an invaluable contribution to Foresite Capital as it moves on to expand in order to diversify its portfolio of several transformational companies.
- He was working as the senior director and looking at scientific research at Illumina. This was when Dr. He looked at the protein reagent innovation as well as improvements for the company globally. Before this, she was at Pacific Biosciences. Here she was heading protein sciences. She was looking after the development of protein reagent for the real-time sequencing chemistry of single molecule. She has over ten years of experience in the pharmaceutical industry. She focuses on the structural design of antibody as well as small molecule drugs. These are the drugs that target cancer as well as immune diseases.
According to Biz Journals, she has a Bachelor’s degree in biochemistry. She earned this from the Nankai University. She has a Ph.D. in protein biophysics. She has earned it from the University of California, Los Angeles. Dr. He has written over 20 published papers. She has over 20 patents in her name. These are in the area of next-generation sequencing as well as personalized medicine.
Jim Tananbaum is the CEO of Foresite Capital. This firm is responsible for providing growth capital to several emerging leaders in healthcare. These are looking into disruptive products as well as services across various healthcare sectors. It caters to the private as well as the public markets.